May 18th brought news from Moderna (MRNA) of the very first human results from trials of their closely-watched mRNA vaccine candidate (mRNA-1273) against the coronavirus. Here's Stat on the news, and here's Endpts - the results can be summed up pretty quickly, because it's all just at the press-release level to start with.
The trial was dosing volunteers in Phase I at three levels 25 micrograms, 100 micrograms, and 250 micrograms of the mRNA species. First off, immunogenicity (whether or not these doses caused people to produce antibodies). The good news there is that every